BioAscent’s Compound Cloud is a unique on-demand service providing rapid and cost-effective access to custom or pre-selected compound libraries. With access to over 125,000 lead-like and drug-like compounds, customers can cherry-pick the compounds they are interested in and have them delivered in a screen-ready format.
In a recent survey, Compound Cloud customers identified competitive cost, the ability to pick custom sub-sets and flexibility in plating as the three top drivers behind using the service.
When asked about their experience of purchasing compounds, the respondents were unanimous, stating that the BioAscent team kept them well informed from ordering through to delivery. Equally, all respondents scored the speed of response to their enquiry as ‘fast to very fast’.
Of particular interest, respondents cited excellent service, better value for money, speed of response and turnaround, and cost as the key areas where Compound Cloud excels against other providers in the market.
BioAscent’s Chief Operating Officer, Sylviane Boucharens, said:
“Compound Cloud’s unique on demand service is attractive to our customers. The survey feedback helps us understand what we are doing well and also where we can improve. For example, customers are keen to see us add compound structure viewing/filtering to the website. We can look at this and other ideas as we develop and enhance the Compound Cloud service moving forward.”
100% of respondents said they would recommend BioAscent’s Compound Cloud service to their peers and colleagues. The quality of the service was recognised in a recent publication as a key resource for high-quality screening compound sets for drug discovery groups with limited resources.
There have been a number of published success stories and projects where the library has been used. These include:
- BioAscent’s collaboration with Heriot-Watt University to identify a molecule that could be used to stop heart stents failing.
- ALBORADA’s Drug Discovery Institute’s use of the library for virtual screening and to progress promising leads against a novel Huntington’s disease target.
- An assay development project at the European Screening Centre.
To find out more about the unique, on-demand Compound Cloud service, click here.